On November 16, 2025, the 6th Nanshan Conference on Precision Treatment of Hematologic Tumors and Advances in Infection Immunology and Microecology Research, hosted by the Guangdong Preventive Medicine Association and organized by Shenzhen University Affiliated Nanshan Hospital, was grandly held at the International Banquet Hall of Star River Bay Peninsula Hotel in Guangzhou. The conference brought together leading experts and scholars in the field of hematologic tumors in China, who delved into industry trends and technological breakthroughs through academic presentations and thematic discussions. Professor Shi Yuanyuan, founder and chairman of Shenzhen Cell Valley, was invited to attend the main event and delivered a keynote speech titled 'Prospects of Cell Therapy under the New Policy of Decree No. 818,' which sparked enthusiastic responses from the audience.

As a seasoned practitioner in the field of cell therapy, Professor Shi Yuanyuan 's presentation closely followed the industry's policy trends, offering an in-depth interpretation of the 'Regulations on the Clinical Research and Clinical Translation of New Biomedical Technologies' (Decree No. 818) issued by the State Council. Officially promulgated in September 2025, the decree explicitly classifies cell therapy as a new biomedical technology and establishes the principle of 'innovation-driven, safety-first' development, effective from May 1, 2026. Professor Shi Yuanyuan noted: 'The introduction of Decree No. 818 marks a new phase of 'standardized innovation' for China's cell therapy industry. The reform of the filing system and the requirements for full-process quality control not only set safety boundaries for technology translation but also create growth opportunities for compliant enterprises.'

During the speech, Professor Shi Yuanuan drew upon his extensive practical experience in the field of cell therapy to elaborate on three key dimensions: policy implementation, developmental bottlenecks, and the advantages of Cell Valley. He emphasized that the advancement of cell therapy under the new policy framework must focus on the following core directions: first, establishing a non-clinical research system compliant with regulatory requirements to lay a solid foundation for clinical applications with robust preclinical data; second, strengthening the qualification development of clinical research institutions and rigorously fulfilling the review responsibilities of academic and ethics committees. At the same time, Professor Shi Yuanuan highlighted the unique advantages of Cell Valley in the cell therapy industry. He pointed out that Cell Valley, leveraging its comprehensive industrial ecosystem, top-tier research platform clusters, efficient resource integration capabilities, and policy support, has established an end-to-end service system spanning early-stage research services, cell preparation and quality control to clinical translation, facilitating the rapid deployment of high-quality cell therapy technologies. Addressing concerns from clinical researchers regarding product safety and efficacy, he also shared data from Cell Valley's extensive clinical studies—as the global service platform with the most single-enterprise pipelines—demonstrating an overall efficacy rate of nearly 80% in treating hematologic malignancies.

The presentation garnered high praise from attending experts for its insightful policy analysis. Professor Shi Yuanuan stated that Cell Valley will actively comply with the requirements of Decree No. 818, continue to deepen its R&D efforts in cell therapy technologies, and strengthen collaboration with clinical institutions to bring more treatment hope to cancer patients. During the conference, Professor Shi Yuanuan was re-elected as a standing committee member of the second term of the Guangdong Preventive Medicine Association's Hematologic Malignancy Prevention and Treatment Professional Committee.